C1498-Luc-mCherry: A Syngeneic Acute Myeloid Leukemia (AML) Model

Acute myeloid leukemia (AML) is the most common hematologic malignancy in adults with a 5-year survival rate of ~25% following diagnosis.[1] While two-thirds of AML patients treated with standard high dose chemotherapy achieve remission, 50% of patients relapse after remission. The majority of relapses occur within two to three years of initial treatment, and every … Continue reading C1498-Luc-mCherry: A Syngeneic Acute Myeloid Leukemia (AML) Model